The short answer
A distinct strand of the KPV literature does not use the tripeptide as an active agent at all. It attaches KPV to a fluorophore or a drug-loaded nanoparticle and uses its affinity for PepT1 to direct the construct toward cells that overexpress the transporter.
Key facts
- Underlying property used
- High affinity for PepT1
- Why it works as an address
- PepT1 is overexpressed in inflamed colonic epithelium
- Fluorescent probe
- DCM-KPV (Zeng M et al., 2017)
- Probe outcome
- Distinguished chronic, acute and normal groups
- Nanoparticle system
- CyA-PLGA-KPV/MMT/CS (Wu Y et al., 2019)
- Target cells named
- Colonic epithelial cells and macrophages
- Retention in inflamed tissue
- Up to 36 hours
- Notable control result
- The carrier without cyclosporine also showed effects
A different use for the same molecule
Most writing about KPV treats it as an agent: give the tripeptide, measure what changes. A growing part of the published work treats it as a postcode. If PepT1 is overexpressed on the surface of particular cells, and KPV binds PepT1 with high affinity, then attaching KPV to something else turns that something else into a molecule that preferentially reaches those cells. The tripeptide is not the point of the experiment; the delivery is.
The imaging application
Zeng and colleagues built a fluorescent probe by conjugating KPV to a dicyanomethylene-4H-pyran chromophore, producing DCM-KPV. The rationale is set out clearly in the paper: PepT1 is overexpressed in the colonic epithelial cells of chronic ulcerative colitis and can carry KPV into the cytosol, so the KPV moiety supplies a specific receptor-targeted interaction. The construct was reported to have long-wavelength emission, low photobleaching and negligible cytotoxicity, to accumulate in the cytoplasm and nucleus of an ulcerative colitis model in Caco-2 cells, and to distinguish chronic from acute ulcerative colitis and from normal tissue in animals. The paper also confirms, incidentally, what KPV is: the C-terminal sequence of alpha-MSH.
Research material referenced
KPV 10mg, third-party HPLC tested
The drug delivery application
Wu and colleagues went further and used KPV to steer a therapeutic payload. Their system is a PLGA nanoparticle bearing KPV, coated with montmorillonite and chitosan, loaded with cyclosporine A. Each component has a stated job: the coating reduces leakage in the upper gastrointestinal tract and improves adhesion to inflamed colon, and the KPV supplies the targeting, described as directing the particle to colonic epithelial cells and macrophages via overexpressed PepT1. Biodistribution showed accumulation in inflamed tissue with retention up to 36 hours, and treated mice in a dextran sulfate sodium colitis model showed improvements in body weight, colon length and disease activity index.
The control result that complicates the story
That paper reports something that deserves more attention than it usually gets: the nanoparticle system without cyclosporine also produced marked effects. Read one way that is a bonus, and the authors treat it as intriguing. Read more carefully it is a problem for attribution. If the carrier alone does much of the work, then the experiment does not cleanly measure what the cyclosporine contributed, and it also does not cleanly measure what the KPV contributed, since the carrier includes both KPV and a mucoadhesive coating with its own physical effects on an inflamed surface. Untangling that would need arms the study did not run.
Why this strand matters for how KPV is described
It suggests that the most robust and reproducible thing about KPV is a transport property rather than a pharmacological one. Researchers reach for it because it reliably binds a transporter that is upregulated where they want to go. That is a real and useful characteristic, and it is a materially different claim from the one usually made about this molecule in retail copy. It also means that a paper with KPV in the title may not be a paper about KPV doing anything. It may be a paper about a dye or a nanoparticle that happens to wear KPV as a label.
How to read this literature
When a KPV paper appears, the first question is which role the tripeptide plays in it. If KPV is the intervention, the relevant controls are vehicle and, ideally, a transport-deficient condition. If KPV is a targeting moiety, the relevant control is the same construct without KPV, and the finding is about the construct. Conflating the two produces claims about a tripeptide that were really about a nanoparticle. None of this work involves humans, and none of it makes KPV a treatment for anything.
Frequently asked questions
Is KPV a drug in these studies?
In the imaging work, no. It is a targeting group attached to a dye. In the nanoparticle work it is a targeting group on a carrier that also holds an actual drug, cyclosporine A, which is a licensed immunosuppressant. The tripeptide's role in both is to help the construct arrive somewhere.
Why is PepT1 overexpression useful for targeting?
Because targeting depends on a difference. A transporter present at low levels in healthy colon and induced during inflammation gives a construct a reason to accumulate in diseased tissue rather than everywhere, which is the central problem in delivery.
Does the 36-hour retention figure apply to KPV itself?
No. It describes how long the nanoparticle system persisted in inflamed tissue in that study. It says nothing about the tripeptide's own behaviour, which is a different molecule with different properties.
Does any of this relate to material sold here?
Only as literature. KPV is supplied here for laboratory research. The constructs described in these papers are purpose-built research materials made in academic laboratories, not products, and none of this work involves human use.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedZeng M et al., Peptide Receptor-Targeted Fluorescent Probe: Visualization and Discrimination between Chronic and Acute Ulcerative Colitis - ACS Appl Mater Interfaces 2017 (PMID 28349696)pubmed.ncbi.nlm.nih.gov
- PubMedWu Y et al., A PepT1 mediated medicinal nano-system for targeted delivery of cyclosporine A to alleviate acute severe ulcerative colitis - Biomater Sci 2019 (PMID 31408067)pubmed.ncbi.nlm.nih.gov
- PubMedDalmasso G et al., PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation - Gastroenterology 2008 (PMID 18061177)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More KPV articles
- A Second Claim, With a Different MechanismWork from 2000 reported that alpha-MSH and its KPV fragment inhibited Staphylococcus aureus and Candida albicans. That is not the anti-inflammatory claim.
- The Part of the Hormone That Talks to the Receptor Is Not in KPVMelanocortin receptor activation requires the His-Phe-Arg-Trp core, and that tetrapeptide alone is an agonist. KPV is residues 11 to 13 and contains none of it.
- Nanomolar in a Dish Is Not a DoseAlmost every quantitative claim about KPV traces back to immortalised cell lines and mouse models. Here is precisely what each of those can and cannot support.
- What Is KPV? The Tripeptide From Alpha-MSHKPV is Lys-Pro-Val, the C-terminal tripeptide of alpha-MSH, at 342.43 Da. It carries reported anti-inflammatory activity without the pigmentation effects.
- Alpha-MSH: Pigmentation and Inflammation in One HormoneA 13-residue hormone doing two unrelated jobs. Why separating its anti-inflammatory C-terminus from its pigmentation activity was worth attempting.